Ramelteon , ≥99% , 196597-26-9

Synonym(s):
(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide;N-[2-[(8S)-1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propanamide;Ramelteon solution;TAK 375;TAK-375

CAS NO.：196597-26-9

Empirical Formula: C16H21NO2

Molecular Weight: 259.34

MDL number: MFCD08067736

EINECS: 200-835-2

PRODUCT Properties

• Melting point: 113-1150C
• alpha: D20 -57.8° (c = 1.004 in chloroform)
• Boiling point: 455.3±24.0 °C(Predicted)
• Density: 1.119±0.06 g/cm3(Predicted)
• Flash point: 2℃
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• solubility: Dimethyl Sulfoxide, Ethanol, Methanol,
• form: Solid
• pka: 16.37±0.46(Predicted)
• color: Crystalline
• InChI: InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
• InChIKey: YLXDSYKOBKBWJQ-LBPRGKRZSA-N
• SMILES: C(NCC[C@H]1C2=C3CCOC3=CC=C2CC1)(=O)CC
• CAS DataBase Reference: 196597-26-9(CAS DataBase Reference)

Description and Uses

Ramelteon, also known as N-[2-[(8S)-1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]propanamide, is a melatonin agonist developed by Takeda Pharmaceuticals, Inc. It was approved by the FDA for marketing in the United States in September 2005 and is marketed under the name Rozerem. It is used to treat difficult-to-sleep and short-term insomnia. Ramelteon is effective for both chronic and short-term insomnia. Unlike most treatments of insomnia that target the GABA (g-aminobutyric acid) receptor complex, ramelteon is an agonist of the melatonin receptor. In particular, it has high selectivity for the MT1 and MT2 subtypes, which have been implicated in the maintenance of circadian rhythms, over the MT3 receptor responsible for other melatonin functions. Its lack of affinity for not only the GABA receptor complex but also neurotransmitter, dopaminerigic, opiate, and benzodiazepine receptors suggests an improved safety profile devoid of the abuse potential of the hypnotic drugs that target these receptors. As such, ramelteon is not a scheduled drug.

Ramelteon is a selective melatonin receptor agonist of MT1 and MT2 approved for the treatment of insomnia (trouble in sleeping). It acts as a sedative and hypnotic agent. Ramelteon is the only prescription sleep aid not designated as a Schedule IV controlled substance.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P301+P312+P330
• Hazard Codes: F,Xn
• Risk Statements: 11-20/21/22-36
• Safety Statements: 16-36/37
• RIDADR: UN 1648 3 / PGII
• WGK Germany: 2
• HS Code: 2932.99.7000
• Hazardous Substances Data: 196597-26-9(Hazardous Substances Data)